Differential activation of the IGF binding protein-3 promoter by butyrate in prostate cancer cells

Endocrinology

Volumn 143, Issue 5, 2002, Pages 1778-1788

  Tsubaki, Junko ^a   Hwa, Vivian ^a   Twigg, Stephen M ^b   Rosenfeld, Ron G ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; HISTONE DEACETYLASE; LUCIFERASE; SOMATOMEDIN BINDING PROTEIN 3; TRICHOSTATIN A;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER CELL; GENE DELETION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; TATA BOX; TRANSACTIVATION; TUMOR GROWTH;

EID: 0036231748     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.143.5.8766     Document Type: Article

References (63)

1. Short chain fatty acids in human large intestine, portal, hepatic and venous blood
2. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate
3. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model
4. Tributyrin induces differentiation, growth arrest and apoptosis in androgen-sensitive and androgen-resistant human prostate cancer cell lines
5. Sodium butyrate inhibits histone deacetylation in cultured cells
6. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors
7. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
8. WAF1/Cip1 and gelsolin
9. WAF1 expression and gene-associated histone acetylation
10. Induction of γ-globin by histone deacetylase inhibitors
11. WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells
12. In vivo mapping of the human adenine nucleotide translocator-2 (ANT2) promoter provides support for regulation by a pair of proximal Sp1-activating sites and an upstream silencer element
13. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor β type II receptor expression in human breast cancer cells
14. Expression of 15-lipoxygenase-1 is regulated by histone acetylation in human colorectal carcinoma
15. Effects of sodium butyrate on expression of members of the IGF-binding protein superfamily in human mammary epithelial cells
16. Insulin-like growth factor-binding proteins in serum and other biological fluids: Regulation and functions
17. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism
18. Insulin-like growth factor binding protein-3. Organization of the human chromosomal gene and demonstration of promoter activity
19. Cloning and characterization of the promoter for the rat insulin-like growth factor-binding protein-3 gene
20. Bovine insulin-like growth factor binding protein-3: Organization of the chromosomal gene and functional analysis of its promoter
21. Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: Molecular mechanism involves an Sp1/Sp3 multiprotein complex
22. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line
23. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites
24. WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites
25. (Waf1/Cip1/Sdi1) gene by c-jun through Sp1 site
26. waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells
27. Sequence-specific DNA binding by p53: Identification of target sites and lack of binding to p53-MDM2 complexes
28. Signalling pathways involved in antiproliferative effects of IGFBP-3: A review
29. TRANSFAC: An integrated system for gene expression regulation
30. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles
31. Enhanced p53 activity and accumulation in response to DNA damage upon DNA transfection
32. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): Dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway
33. Butyric acid induces apoptosis by up-regulating Bax expression via stimulation of the c-Jun N-terminal kinase/activation protein-1 pathway in human colon cancer cells
34. Effects of sodium butyrate on the synthesis and methylation of DNA in normal cells and their transformed counterparts
35. DNA hypermethylation in sodium butyrate-treated WI-38 fibroblasts
36. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A
37. Modulating IGFBP-3 expression by trichostatin A: Potential therapeutic role in the treatment of hepatocellular carcinoma
38. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor β2-induced growth inhibition in human breast cancer cells
39. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3
40. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells
41. Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breast cancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation
42. Induction of the growth inhibitor IGF-binding protein 3 by p53
43. Transcriptional regulation by butyrate of mouse galectin-1 gene in embryonal carcinoma cells
44. Sodium butyrate induces transcription from the Gα i2 gene promoter through multiple Sp1 sites in the promoter and by activating the MEK-ERK signal transduction pathway
45. Transcriptional regulation of the mouse ferritin H gene. Involvement of p300/CBP adaptor proteins in FER-1 enhancer activity
46. waf1/cip1 promoter activation induced by histone deacetylase inhibitor
47. ZBP-89 promotes growth arrest through stabilization of p53
48. Increased gamma-globin expression in a nondeletion HPFH mediated by an erythroid-specific DNA-binding factor
49. A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer
50. Genes modulated by histone acetylation as new effectors of butyrate activity
51. Extended survivability of prostate cancer cells in the absence of trophic factors: Increased proliferation, evasion of apoptosis, and the role of apoptosis proteins
52. Deacetylation of p53 modulates its effect on cell growth and apoptosis
53. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a
54. Definition of a consensus binding site for p53
55. Further characterisation of the p53 responsive element - Identification of new candidate genes for trans-activation by p53
56. Butyrate modulates DNA-damage-induced p53 response by induction of p53-independent differentiation and apoptosis
57. Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells
58. Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines
59. p63 and p73: Old members of a new family
60. p63 is a prostate basal cell marker and is required for prostate development
61. Prostate carcinoma: Tissue culture cell lines
62. LNCaP model of human prostatic carcinoma
63. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells